Curtana Pharmaceuticals
Manufacturing · Texas, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4200 Marathon Blvd Ste 200, Austin, Texa...Phone Number
(512) 900-3696Website
www.curtanapharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Curtana Pharmaceuticals
Curtana Pharmaceuticals is focused on developing highly targeted therapies for brain cancer, specifically glioblastoma in adults and medulloblastoma in children. Their lead product, CT-179, is a first-in-class small molecule inhibitor of OLIG2, aimed at addressing the root causes of tumor growth and resistance. Founded in 2013, the company has received FDA designations for its investigational drug and plans to initiate Phase 1 clinical trials soon. With a leadership team experienced in cancer treatment development, Curtana is committed to improving survival outcomes for patients facing aggressive brain cancers.Explore more
Curtana Pharmaceuticals Org Chart
LT
Vice President, Toxicology & Nonclinical Deve...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Curtana Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Curtana Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Curtana Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Curtana Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Curtana Pharmaceuticals
Website visits: Recent activity has been detected on your website
Check out if Curtana Pharmaceuticals is spiking on competitors!
Curtana Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Curtana Pharmaceuticals launches new products
Earning: See what the market has to say on Curtana Pharmaceuticals recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Curtana Pharmaceuticals
Compare insights from companies similar to Curtana Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Curtana Pharmaceuticals
<$5M
1-10
Private
$7.6M
2013
FD
Frank Del GrecoVice President, Clinical Operations
Company Profile Activity
Activity Insights
Curtana Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Curtana Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Curtana Pharmaceuticals.
Curtana Pharmaceuticals financials insights
Gather financial insights about Curtana Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Grant
$7.6M
Curtana Pharmaceuticals Tech Stack
A closer look at the technologies used by Curtana Pharmaceuticals
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Curtana Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Curtana Pharmaceuticals is focused on developing highly targeted therapies for brain cancer, specifically glioblastoma in adults and medulloblastoma in children. Their lead product, CT-179, is a first-in-class small molecule inhibitor of OLIG2, aimed at addressing the root causes of tumor growth and resistance. Founded in 2013, the company has rece... Read More
